These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 30396317

  • 21. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis].
    Meng ZY, Zhang JY, Zhang ZG, Luo D, Yang XM.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Dec 10; 39(12):1636-1641. PubMed ID: 30572392
    [Abstract] [Full Text] [Related]

  • 22. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP, Robertson CA, Talbot HK, Decker MD.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2058-2064. PubMed ID: 28700265
    [Abstract] [Full Text] [Related]

  • 23. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
    Lee J, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Hong YJ, Choi YY, Jo DS, Ma SH, Kang JH.
    J Korean Med Sci; 2018 Mar 26; 33(13):e100. PubMed ID: 29573247
    [Abstract] [Full Text] [Related]

  • 24. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.
    Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, Halperin SA, Li P, Liu A, McNeil S, Mendez LP, Rivera L, Innis BL, Jain VK.
    J Pediatric Infect Dis Soc; 2015 Sep 26; 4(3):242-51. PubMed ID: 26336604
    [Abstract] [Full Text] [Related]

  • 25. A Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age.
    Eun BW, Lee TJ, Lee J, Kim KH, Kim DH, Jo DS, Shin SH, Kim H, Kim KH, Kim YK.
    Pediatr Infect Dis J; 2019 Sep 26; 38(9):e209-e215. PubMed ID: 31335572
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, Heijnen E, Edelman J, Marshall GS.
    Vaccine; 2019 Jan 07; 37(2):343-351. PubMed ID: 30057283
    [Abstract] [Full Text] [Related]

  • 27. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 28. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, QHD00013 Study Group.
    Vaccine; 2019 Sep 16; 37(39):5825-5834. PubMed ID: 31431411
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M, Tarigan R, Fadlyana E, Prasetyo D, Amalia N, Rusmil VK, Sari RM, Bachtiar NS, Rusmil K, Kartasasmita CB.
    Vaccine; 2020 Jan 29; 38(5):993-1000. PubMed ID: 31862195
    [Abstract] [Full Text] [Related]

  • 30. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, Matassa V, Leong J.
    Vaccine; 2017 Apr 04; 35(15):1856-1864. PubMed ID: 28302411
    [Abstract] [Full Text] [Related]

  • 31. Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged ≥ 65 years.
    Kim TH, Choi JH, Park SH, Yoo JH, Lee DG, Choi SM, Kim YR, Lee MS, Choo EJ, Choi HJ.
    Vaccine; 2021 Jun 16; 39(27):3621-3625. PubMed ID: 33992436
    [Abstract] [Full Text] [Related]

  • 32. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB.
    Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA, Ribeiro Dos Santos R, Jose Nunes M, Soni J, Li P, Jain VK, Ofori-Anyinam O.
    Braz J Infect Dis; 2017 Nov 14; 21(1):63-70. PubMed ID: 27912069
    [Abstract] [Full Text] [Related]

  • 34. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, Kowalska E, Van Damme P, Salamand C, Pepin S.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):596-608. PubMed ID: 28968138
    [Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Chang CY, Cho CY, Lai CC, Lu CY, Chang LY, Hung MC, Huang LM, Wu KG.
    Vaccine; 2020 May 08; 38(22):3839-3846. PubMed ID: 32284272
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis.
    Liang Y, Jing-Xia G, Ma L, Ni L, Chaolie R, Zhou J, Guo-Yang L.
    Hum Vaccin Immunother; 2021 Oct 03; 17(10):3652-3661. PubMed ID: 34156322
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.
    Bart S, Cannon K, Herrington D, Mills R, Forleo-Neto E, Lindert K, Abdul Mateen A.
    Hum Vaccin Immunother; 2016 Sep 03; 12(9):2278-88. PubMed ID: 27322354
    [Abstract] [Full Text] [Related]

  • 38. Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults.
    Fadlyana E, Dhamayanti M, Tarigan R, Prodjosoewojo S, Rahmadi AR, Sari RM, Rusmil K, Kartasasmita CB.
    PLoS One; 2023 Sep 03; 18(8):e0281566. PubMed ID: 37616221
    [Abstract] [Full Text] [Related]

  • 39. Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.
    Hartvickson R, Cruz M, Ervin J, Brandon D, Forleo-Neto E, Dagnew AF, Chandra R, Lindert K, Mateen AA.
    Int J Infect Dis; 2015 Dec 03; 41():65-72. PubMed ID: 26585940
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.